Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure (CCT-IOP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00941525|
Recruitment Status : Completed
First Posted : July 17, 2009
Last Update Posted : July 7, 2015
The purpose of this study is to determine whether 24-hour fluctuation of intraocular pressure (IOP) is associated with central corneal thickness (CCT) in subjects with ocular hypertension or open angle glaucoma and in age-matched controls. Also to evaluate whether mean IOP reduction as a response to latanoprost (0.005% Xalatan) is associated with CCT, after a 4-weeks period of treatment.
Also, to evaluate whether 24-hour fluctuation of IOP is associated with corneal hysteresis (CH) measured by Ocular Response Analyzer (ORA).
|Condition or disease||Intervention/treatment||Phase|
|Open Angle Glaucoma Ocular Hypertension||Drug: Latanoprost||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||174 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||July 2014|
|Actual Study Completion Date :||July 2014|
U.S. FDA Resources
This study includes two groups.
1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
Other Name: 0.005% Xalatan
- Correlation analyses between mean central corneal thickness (CCT) and 24-hour intraocular pressure (IOP) fluctuation and between mean CCT and mean IOP reduction from baseline after a 4-weeks period of treatment with latanoprost. [ Time Frame: Before and after a 4-weeks period of treatment with latanoprost. ]
- Correlation analyses between corneal hysteresis (CH) and 24-hour intraocular pressure (IOP) fluctuation and between CH and mean IOP reduction from baseline after a 4-weeks period of treatment with latanoprost. [ Time Frame: Before and after a 4-weeks period of treatment with latanoprost. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00941525
|A' Department of Ophthalmology, Aristotle University of Thessaloniki, AHEPA Hospital|
|Thessaloniki, Greece, 54636|
|Principal Investigator:||Fotis Topouzis, MD||Aristotle University Of Thessaloniki|